Abstract:What's new? Heterogeneity in breast cancer contributes to variations in treatment effectiveness. Patient‐derived organoids (PDOs) have emerged as promising models to predict individualized drug responses, though their applicability to breast cancer remains largely unexplored. Here, the authors established a biobank of breast cancer PDOs to evaluate their feasibility in predicting patient drug response. Experiments demonstrate that the PDOs accurately inherit the histologic and genetic characteristics of the breast tumors from which they are derived. Moreover, drug susceptibility in PDOs corresponded to clinical responses in matched patients. The findings highlight the potential utility of PDOs in guiding personalized therapy for breast cancer patients. Breast cancer has become the most commonly diagnosed cancer. The intra‐ and interpatient heterogeneity induced a considerable variation in treatment efficacy. There is an urgent requirement for preclinical models to anticipate the effectiveness of individualized drug responses. Patient‐derived organoids (PDOs) can accurately recapitulate the architecture and biological characteristics of the origin tumor, making them a promising model that can overtake many limitations of cell lines and PDXs. However, it is still unclear whether PDOs‐based drug testing can benefit breast cancer patients, particularly those with tumor recurrence or treatment resistance. Fresh tumor samples were surgically resected for organoid culture. Primary tumor samples and PDOs were subsequently subjected to H&E staining, immunohistochemical (IHC) analysis, and whole‐exome sequencing (WES) to make comparisons. Drug sensitivity tests were performed to evaluate the feasibility of this model for predicting patient drug response in clinical practice. We established 75 patient‐derived breast cancer organoid models. The results of H&E staining, IHC, and WES revealed that PDOs inherited the histologic and genetic characteristics of their parental tumor tissues. The PDOs successfully predicted the patient's drug response, and most cases exhibited consistency between PDOs' drug susceptibility test results and the clinical response of the matched patient. We conclude that the breast cancer organoids platform can be a potential preclinical tool used for the selection of effective drugs and guided personalized therapies for patients with advanced breast cancer.

Patient-derived organoids in precision cancer medicine

Human patient derived organoids: an emerging precision medicine model for gastrointestinal cancer research

Patient-derived Organoids in Translational Oncology and Drug Screening

Creation and Development of Patient-Derived Organoids for Therapeutic Screening in Solid Cancer

Patient-derived organoids in human cancer: a platform for fundamental research and precision medicine

Patient‐derived Cancer Organoids for Drug Screening: Basic Technology and Clinical Application

Tumor organoids: synergistic applications, current challenges, and future prospects in cancer therapy

Patient-derived Organoids (pdos) and PDO-derived Xenografts (pdoxs): New Opportunities in Establishing Faithful Pre-Clinical Cancer Models

The future of cancer therapy: exploring the potential of patient-derived organoids in drug development

Organoids: An intermediate modeling platform in precision oncology.

Patient‐Derived Organoids as Therapy Screening Platforms in Cancer Patients

Cancer organoids: A platform in basic and translational research

Patient-derived tumor organoids: a new avenue for preclinical research and precision medicine in oncology

Gastrointestinal Cancer Patient Derived Organoids at the Frontier of Personalized Medicine and Drug Screening

Patient-Derived Tumor Organoids: New Progress and Opportunities to Facilitate Precision Cancer Immunotherapy

Patient-Derived Organoids: A Game-Changer in Personalized Cancer Medicine

Tumor organoids: From inception to future in cancer research

Organoids: approaches and utility in cancer research

Tumor Organoids: The Era of Personalized Medicine

Organoids for Cancer Research: Advances and Challenges

Establishment of patient‐derived organoids for guiding personalized therapies in breast cancer patients